Inventor
MILONE MICHAEL C
US40 patents
⚠️ This page may combine multiple inventors who share the name “MILONE MICHAEL C”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
UNIV PENNSYLVANIA
24 patentsUS9540445B2Jan 10, 2017
Compositions and methods for treatment of cancer
UNIV PENNSYLVANIA99 citations99
US9518123B2Dec 13, 2016
Compositions and methods for treatment of cancer
UNIV PENNSYLVANIA92 citations99
US9481728B2Nov 1, 2016
Compositions and methods for treatment of cancer
UNIV PENNSYLVANIA100 citations99
US9464140B2Oct 11, 2016
Compositions and methods for treatment of cancer
UNIV PENNSYLVANIA117 citations99
US9328156B2May 3, 2016
Use of chimeric antigen receptor-modified T cells to treat cancer
UNIV PENNSYLVANIA127 citations99
US9102761B2Aug 11, 2015
Compositions for treatment of cancer
UNIV PENNSYLVANIA250 citations99
US9101584B2Aug 11, 2015
Methods for treatment of cancer
UNIV PENNSYLVANIA250 citations99
US9102760B2Aug 11, 2015
Compositions for treatment of cancer
UNIV PENNSYLVANIA254 citations99
US8975071B1Mar 10, 2015
Compositions for treatment of cancer
UNIV PENNSYLVANIA255 citations99
US8916381B1Dec 23, 2014
Methods for treatment of cancer
UNIV PENNSYLVANIA276 citations99
US8911993B2Dec 16, 2014
Compositions for treatment of cancer
UNIV PENNSYLVANIA474 citations99
US8906682B2Dec 9, 2014
Methods for treatment of cancer
UNIV PENNSYLVANIA507 citations99
US10273300B2Apr 30, 2019
Methods of making chimeric antigen receptor-expressing cells
UNIV PENNSYLVANIA26 citations92
US10301370B2May 28, 2019
Compositions and methods of chimeric autoantibody receptor T cells
UNIV PENNSYLVANIA6 citations82
US10851149B2Dec 1, 2020
Treatment of cancer using GFR α-4 chimeric antigen receptor
UNIV PENNSYLVANIA3 citations72
US11407803B2Aug 9, 2022
Compositions and methods of chimeric autoantibody receptor T cells
UNIV PENNSYLVANIA1 citations71
US10738099B2Aug 11, 2020
Method of redirecting T cells to treat HIV infection
UNIV PENNSYLVANIA2 citations69
US11970525B2Apr 30, 2024
Treatment of cancer using GFR alpha-4 chimeric antigen receptor
UNIV PENNSYLVANIA0 citations62
US12214037B2Feb 4, 2025
Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
UNIV PENNSYLVANIA0 citations61
US11578113B2Feb 14, 2023
Compositions and methods of chimeric autoantibody receptor T cells
UNIV PENNSYLVANIA0 citations60
US11407802B2Aug 9, 2022
Compositions and methods of chimeric autoantibody receptor T cells
UNIV PENNSYLVANIA0 citations60
US11407804B2Aug 9, 2022
Compositions and methods of chimeric autoantibody receptor T cells
UNIV PENNSYLVANIA0 citations60
US12122820B2Oct 22, 2024
Method of redirecting t cells to treat HIV infection
UNIV PENNSYLVANIA0 citations59
US11905321B2Feb 20, 2024
Compositions and methods of muscle specific kinase chimeric autoantibody receptor cells
UNIV PENNSYLVANIA0 citations56
NOVARTIS AG
12 patentsUS9745368B2Aug 29, 2017
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
NOVARTIS AG117 citations97
US10174095B2Jan 8, 2019
Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor
NOVARTIS AG41 citations96
US11084880B2Aug 10, 2021
Anti-BCMA chimeric antigen receptor
NOVARTIS AG15 citations93
US10577417B2Mar 3, 2020
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
NOVARTIS AG10 citations82
US12240884B2Mar 4, 2025
Methods for improving the efficacy and expansion of immune cells
NOVARTIS AG2 citations72
US10568947B2Feb 25, 2020
Treatment of cancer using a CLL-1 chimeric antigen receptor
NOVARTIS AG6 citations71
US11591404B2Feb 28, 2023
Treatment of cancer using a CD123 chimeric antigen receptor
NOVARTIS AG0 citations62
US11919946B2Mar 5, 2024
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
NOVARTIS AG0 citations61
US11578130B2Feb 14, 2023
Regulatable chimeric antigen receptor
NOVARTIS AG1 citations61
US11459390B2Oct 4, 2022
Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
NOVARTIS AG0 citations61
US11981731B2May 14, 2024
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
NOVARTIS AG0 citations60
US11896614B2Feb 13, 2024
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
NOVARTIS AG0 citations48